30 closest matches · ranked by relevance
Multifocal Motor Neuropathy (MMN)
Primary: Change From Baseline to Week 24 in Muscle Strength — 0.4 score on a scale
Multifocal Motor Neuropathy
Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms
Multifocal Motor Neuropathy
Primary: Number of Participants With AEs and SAEs — 14; 5; 14; 6 Participants
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Myeloma
Primary: The Difference Between Touch Detection Thresholds From the Sensorimotor Evaluation at Baseline and After 10 Weeks of Induction Therapy. — 0.00; 0.06; 0.08; 0.13 mN…
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
Myasthaenia Gravis
Primary: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24 — -2.37; -4.21 Units on a scale — p=0.256
Generalized Myasthenia Gravis
Primary: Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo. — 17; 6…
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Myasthenia Gravis
Primary: To Determine the Effect of Acupuncture on Quality of Life in Patients With MG — 10.8; 9.4; 3.6; 8.3 score on a scale
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
GNE Myopathy
Primary: Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted) — 7461; 9432 hr*ng/mL
Multiple Sclerosis
Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
Myasthenia Gravis
Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Low Back Disorder
Primary: Success of Pedicle Screw Trajectories — 296; 5; 2 Screws
Generalized Myasthenia Gravis
Primary: Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population — 67.7; 29.7 percentage of patients — p=<0.0001
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672
Myasthenia Gravis
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) — 10; 10; 8; 3 Participants
Myasthenia Gravis, Generalized
Primary: Mean Change From Baseline in the Quantitative Myastenia Gravis (QMG) Score at Week 25. Posterior Median Was Used as Measure Type. — -4.07; -2.93 score
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Duchenne Muscular Dystrophy · Spinal Muscular Atrophy · Congenital Muscular Dystrophy
Primary: Geometric Mean Titer Ratio for Each Vaccine Strain — 3.76; 3.53; 2; 1.46 geometric mean titer ratio — p=<.05